

# Jeremy M Murray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3430557/publications.pdf>

Version: 2024-02-01

19  
papers

1,343  
citations

566801

15  
h-index

752256

20  
g-index

20  
all docs

20  
docs citations

20  
times ranked

2497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2576-2607.	2.9	91
2	Inhibition of <i>Escherichia coli</i> Lipoprotein Diacylglyceryl Transferase Is Insensitive to Resistance Caused by Deletion of Braunâ€™s Lipoprotein. <i>Journal of Bacteriology</i> , 2021, 203, e0014921.	1.0	16
3	Unstable Mechanisms of Resistance to Inhibitors of <i>Escherichia coli</i> Lipoprotein Signal Peptidase. <i>MBio</i> , 2020, 11, .	1.8	15
4	Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2140-2153.	2.9	29
5	Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms. <i>Drug Discovery Today: Technologies</i> , 2019, 31, 109-123.	4.0	40
6	GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9301-9315.	2.9	11
7	Optimized arylomycins are a new class of Gram-negative antibiotics. <i>Nature</i> , 2018, 561, 189-194.	13.7	244
8	Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4458-4473.	2.9	18
9	Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3534-3541.	1.0	28
10	USP7 small-molecule inhibitors interfere with ubiquitin binding. <i>Nature</i> , 2017, 550, 534-538.	13.7	258
11	Structural insights into lipoprotein N-acylation by <i>Escherichia coli</i> apolipoprotein N-acyltransferase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6044-E6053.	3.3	50
12	Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death. <i>Cell Death and Differentiation</i> , 2017, 24, 26-37.	5.0	95
13	Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5391-5402.	2.9	95
14	Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation. <i>Structure</i> , 2016, 24, 1335-1345.	1.6	67
15	Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling. <i>Structure</i> , 2016, 24, 179-186.	1.6	171
16	Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5258-5264.	1.0	20
17	Tailoring Small Molecules for an Allosteric Site on Procaspaseâ€™6. <i>ChemMedChem</i> , 2014, 9, 73-77.	1.6	25
18	Modulating caspase activity: beyond the active site. <i>Current Opinion in Structural Biology</i> , 2013, 23, 812-819.	2.6	14

#	ARTICLE	IF	CITATIONS
19	Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3149-3153.	1.0	55